David R Nelson, M.D.

Publications

Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Journal of viral hepatitis
2022

Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014.
Expert review of pharmacoeconomics & outcomes research
2022

Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis.
Hepatology (Baltimore, Md.)
2022

Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection.
Scientific reports
2022

Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
Journal of viral hepatitis
2021

Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
Liver international : official journal of the International Association for the Study of the Liver
2021

Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Journal of hepatology
2021

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
The American journal of gastroenterology
2021

HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017.
Preventive medicine
2021

Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data.
Medicine
2021

Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
Hepatology Communications
2021

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Hepatology (Baltimore, Md.)
2021

Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".
Journal of hepatology
2020

Patient-Centered Covid-19 Screening in a Community of Older Adults: Combining Educational and Research Components
NEJM Catalyst Innovations in Care Delivery
2020

Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
Journal of general internal medicine
2020

DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Journal of hepatology
2020

Audience segmentation as a strategy for enhancing the use of research registries for recruiting patients into clinical trials.
Contemporary clinical trials communications
2020

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.
Hepatology communications
2019

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.
Gastroenterology
2019

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Journal of hepatology
2019

Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research Consortium.
Obesity research & clinical practice
2019

Is Interferon Therapy for Hepatitis C Infection a Treatable Risk Factor for Parkinson Disease?
JAMA neurology
2019

Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Hepatology (Baltimore, Md.)
2019

Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey.
Cancer epidemiology
2019

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Gastroenterology
2019

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Journal of viral hepatitis
2019

Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic.
Annals of hepatology
2019

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.
JAMA network open
2019

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2018

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
Scientific reports
2018

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions
2018

Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients.
Pediatric nephrology (Berlin, Germany)
2018

Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2018

Computable Eligibility Criteria through Ontology-driven Data Access: A Case Study of Hepatitis C Virus Trials.
AMIA ... Annual Symposium proceedings. AMIA Symposium
2018

Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.
Hepatology (Baltimore, Md.)
2018

Characterization of adult obesity in Florida using the OneFlorida clinical research consortium.
Obesity science & practice
2018

A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
PloS one
2018

Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Journal of hepatology
2017

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Hepatology (Baltimore, Md.)
2017

Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
Gastroenterology
2017

Pragmatic trial of a Study Navigator Model (NAU) vs. Ambassador Model (N+) to increase enrollment to health research among community members who use illicit drugs.
Drug and alcohol dependence
2017

Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
Contemporary clinical trials
2017

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Annals of internal medicine
2017

Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics
2017

HBV reactivation after HCV eradication: Deja Vu.
Liver international : official journal of the International Association for the Study of the Liver
2017

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
The Lancet. Infectious diseases
2017

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
The New England journal of medicine
2017

Evaluating the Efficacy of a Registry linked to a Consent to Re-Contact Program and Communication Strategies for Recruiting and Enrolling Participants into Clinical Trials.
Contemporary clinical trials communications
2017

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
The lancet. Gastroenterology & hepatology
2017

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Gut
2017

Consent2Share: an integrated broad consenting process for re-contacting potential study subjects.
Journal of clinical and translational research
2017

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Alimentary pharmacology & therapeutics
2017

A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Molecular therapy : the journal of the American Society of Gene Therapy
2017

Small-Molecule Inhibitor Sorafenib Regulates Immunoreactions By Inducing Survival and Differentiation of Bone Marrow Cells
Innate Immunity
2016

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
Liver international : official journal of the International Association for the Study of the Liver
2016

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
PloS one
2016

On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Liver international : official journal of the International Association for the Study of the Liver
2016

On-Treatment HCV RNa As a Predictor of Sustained Virological Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir
Liver International
2016

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
The Journal of infectious diseases
2016

Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2016

Hepatitis C virus: how to provide the best treatment with what I have.
Liver international : official journal of the International Association for the Study of the Liver
2016

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.
Clinical and experimental gastroenterology
2016

HCVerso 1 and 2: faldaprevir with deleobuvit (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C genotype-1b infection
Clinical and Experimental Gastroenterology
2016

HCV-TARGET Study Group. Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
Gastroenterology
2016

HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.
Liver international : official journal of the International Association for the Study of the Liver
2016

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Gastroenterology
2016

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Gastroenterology
2016

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
2016

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Alimentary pharmacology & therapeutics
2015

Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
Journal of Clinical Gastroenterology
2015

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
Journal of hepatology
2015

Pharmacokinetics of hepatitis C treatment.
Pharmacogenomics Applications to Patient Care
2015

Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver
2015

Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1
Journal of Gastroenterology and Hepatology Research
2015

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Lancet (London, England)
2015

Development of sofosbuvir for the treatment of hepatitis C virus infection.
Annals of the New York Academy of Sciences
2015

Designing a CTSA-Based Social Network Intervention to Foster Cross-Disciplinary Team Science.
Clinical and translational science
2015

Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.
Chronic obstructive pulmonary diseases (Miami, Fla.)
2015

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology (Baltimore, Md.)
2015

Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2015

VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection
European Journal of Gastroenterology & Hepatology
2014

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
New England Journal of Medicine
2014

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
The New England journal of medicine
2014

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
Hepatology
2014

Minimal Impact of Sofosbuvir and Ribavirin On Health Related Quality of Life in Chronic Hepatitis C (Ch-C)
Journal of hepatology
2014

Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Liver international : official journal of the International Association for the Study of the Liver
2014

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
2014

Genome-Wide Association Study To Characterize Serum Bilirubin Elevations in Patients With Hcv Treated With Gs-9256, An Hcv Ns3 Serine Protease Inhibitor
Antiviral Therapy
2014

Effects of Sofosbuvir-Based Treatment, With and Without Interferon, On Outcome and Productivity of Patients With Chronic Hepatitis C
Clinical Gastroenterology and Hepatology
2014

Direct-acting antiviral agents and the path to interferon independence.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2014

Daclatasvir plus sofosbuvir for HCV infection.
The New England journal of medicine
2014

Clinical pharmacogenetics implementation: Approaches, successes, and challenges
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
2014

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
Clinical pharmacology and therapeutics
2014

The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Alimentary pharmacology & therapeutics
2013

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Lancet (London, England)
2013

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
The Lancet. Infectious diseases
2013

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
The New England journal of medicine
2013

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Journal of hepatology
2013

Patient-reported immunosuppression nonadherence 6 to 24 months after liver transplant: association with pretransplant psychosocial factors and perceptions of health status change.
Progress in transplantation (Aliso Viejo, Calif.)
2013

OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Laboratory investigation; a journal of technical methods and pathology
2013

New therapeutic strategies in HCV: second-generation protease inhibitors.
Liver international : official journal of the International Association for the Study of the Liver
2013

Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology
2013

Institutional Profile: University of Florida & Shands Hospital Personalized Medicine Program: Clinical Implementation of Pharmacogenetics
Pharmacogenomics
2013

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Cancer immunology, immunotherapy : CII
2013

Efficacious versus effective: what's in an adjective?
Simulation in healthcare : journal of the Society for Simulation in Healthcare
2013

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology
2013

Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients.
PloS one
2013

CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
Liver international : official journal of the International Association for the Study of the Liver
2013

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.
Gut
2012

Unexpected maintenance of hepatitis C viral diversity following liver transplantation.
Journal of virology
2012

Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008.
BMC research notes
2012

The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
Liver international : official journal of the International Association for the Study of the Liver
2012

The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy
2012

Serum levels of soluble CD25 as a marker for hepatocellular carcinoma.
Oncology letters
2012

Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).
Clinical and translational science
2012

Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2012

Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2012

Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
American journal of clinical oncology
2012

Hepatitis C virus: a critical appraisal of new approaches to therapy.
Hepatitis research and treatment
2012

Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2012

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Annals of hepatology
2012

University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine.
Clinical and translational science
2011

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Liver international : official journal of the International Association for the Study of the Liver
2011

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics
2011

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2011

Response-guided telaprevir combination treatment for hepatitis C virus infection.
The New England journal of medicine
2011

Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cells.
PloS one
2011

Racial differences in hepatitis C treatment eligibility Hepatology
Hepatology
2011

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Alimentary pharmacology & therapeutics
2011

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2011

Once-Daily Psi-7977 Plus Peg/Rbv in Treatment-Naive Patients With Hcv Gt1: Robust End of Treatment Response Rates Are Sustained Post-Treatment
Higher Education Policy
2011

Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.
Clinical transplantation
2011

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Laboratory investigation; a journal of technical methods and pathology
2011

Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation?
Progress in transplantation (Aliso Viejo, Calif.)
2011

Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line
Journal of Viral Hepatitis
2011

Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells.
Virology journal
2011

Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro.
International journal of radiation biology
2011

Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells.
PloS one
2011

Boceprevir for untreated chronic HCV genotype 1 infection
New England Journal of Medicine
2011

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Hepatology
2011

Transfusion has no effect on recurrence in hepatitis C after liver transplantation.
Acta anaesthesiologica Scandinavica
2010

The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Digestive diseases and sciences
2010

Telaprevir for previously treated chronic HCV infection.
The New England journal of medicine
2010

Review article: the management of hepatocellular carcinoma.
Alimentary pharmacology & therapeutics
2010

Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T-cell Function in Hepatocellular Carcinoma
Scandinavian Journal of Immunology
2010

Identifying Hepatitis C Virus Genotype 2/3 Patients Who Can Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin
Hepatology
2010

Identifying HCV genotype 2/3 patients who can receive a 16 week abbreviated course of peginterferon alfa-2a plus ribavirin
Hepatology
2010

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
Gastroenterology
2010

Hepatitis C virus modulates human monocyte-derived dendritic cells.
Journal of viral hepatitis
2010

Fatigue and Sleep Quality before and after Liver Transplantation
Progress in Transplantation
2010

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients.
Viral immunology
2010

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Gastroenterology
2010

Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1
Gastroenterology
2010

Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients
Liver Transplantation
2009

The natural history of hepatitis C cirrhosis after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2009

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
The New England journal of medicine
2009

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2009

STAT-C: New therapies cannot get here fast enough
Current Hepatitis Reports
2009

Ribavirin: current role in the optimal clinical management of chronic hepatitis C.
Journal of hepatology
2009

Novel interferons for treatment of hepatitis c virus
Clinics in Liver Disease
2009

Improving the Standard of Care for HCV Management: Available and Emerging Strategies for Optimal Patient Outcomes
PeerView CME Activity
2009

Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
Digestive Diseases and Sciences
2009

Hepatitis C virus: a critical appraisal of approaches to therapy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2009

Hepatitis C drug development at a crossroads.
Hepatology (Baltimore, Md.)
2009

Gamma radiation alters the phenotype and function of CD4+CD25+ regulatory cells

2009

Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 Or 3
Higher Education Policy
2009

Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapy
Hepatology Research
2009

A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.
Hepatology international
2009

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results
Hepatology
2009

Ribavirin considerations in treatment optimization.
Antiviral therapy
2008

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
Hepatology
2008

Is sonographic surveillance of polytetrafluorethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary? A single center experience comparing both types of stents
Clin Radiol
2008

Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Antiviral therapy
2008

Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 in Hcv Genotype 2 and 3 Prior Non-Responders: Interim Results of R7128 1500Mg Bid With Peg-Ifn and Ribavirin for 28 Days
Higher Education Policy
2008

The failing liver
Audio-Digest Gastroenterology
2007

The Financial Burden of Transplantation: A Single-Center Survey of Liver and Kidney Transplant Recipients
Transplantation
2007

Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
New England Journal of Medicine
2007

New Inhibitors of the HCV Life Cycle
Hot Topics in Viral Hepatitis
2007

Is early recurrence of hepatitis C associated with biliary anastamotic stricture after liver transplantation?
Transplantation
2007

Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells
Laboratory Investigation
2007

Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System
Gastroenterology
2007

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
Hepatology
2007

Current and future hepatitis C therapies
Archives of Medical Research
2007

Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture.
Hepatology research : the official journal of the Japan Society of Hepatology
2007

Viral hepatitis: manifestations and management strategy.
Hematology. American Society of Hematology. Education Program
2006

Longterm care of the liver transplant recipient.
Therapy of Digestive Disorders
2006

Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis
Liver Transplantation
2006

Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation
Liver Transplantation
2006

Global transcriptional effects of PEG-IFN-α and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C
Hepatology Research
2006

Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2006

Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation
Digestive Diseases and Sciences
2006

A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
Antiviral therapy
2006

Short-Recovery Time After Percutaneous Liver Biopsy: Should We Change Our Current Practices?
Clinical Gastroenterology and Hepatology
2005

Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation
Hepatology
2005

Pathogenesis of recurrent hepatitis C after liver transplantation
Current Hepatitis Reports
2005

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
Virology journal
2005

Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C
Liver Transplantation
2005

Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
2005

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
Liver Transplantation
2005

A brief psychological intervention to improve adherence following transplantation.
Annals of transplantation
2005

Tobacco use before and after liver transplantation: A single center survey and implications for clinical practice and research
Liver Transplantation
2004

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Liver Transplantation
2004

One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Liver Transplantation
2004

Keratin 8 and 18 hyperphosphorylation is a marker of human liver disease progression
Hepatology
2004

An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Hepatology
2004

Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.
Hepatology (Baltimore, Md.)
2003

Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection
Liver Transplantation
2003

Immunopathogenesis of Viral Hepatitis
Hepatitis: Index & Reviews
2003

Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line
Hepatology
2003

CD8+ T-cell interaction with HCV replicon cells: Evidence for both cytokine- and cell-mediated antiviral activity
Hepatology
2003

Liver transplantation for Hepatocellular carcinoma
Acta Minerva Surgical
2002

Interleukin-10 Inhibition of Nitric Oxide Biosynthesis Involves Suppression of CAT-2 Transcription
Nitric Oxide
2002

Future Drug Development
Clinicians Companion VI: Experts Perspectives on Contemporary Clinical Issues in Hepatitis C
2002

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Liver Transplantation
2002

The immunopathogenesis of hepatitis C virus infection.
Clinics in liver disease
2001

Host immune response in pathogenesis of hepatitis C
The Clinician’s Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C
2001

Combined hepatic resection and radiofrequency ablation for hepatic adenomatosis
HPB Surgery
2001

Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2001

Interleukin-12 production in chronic hepatitis C infection
Journal of Hepatology
2000

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Gastroenterology
2000

THE UTILITY OF NONINVASIVE SEROLOGIC MARKERS IN THE MANAGEMENT OF EARLY ALLOGRAFT REJECTION IN LIVER TRANSPLANTATION RECIPIENTS1
Transplantation
1999

Future options for the management of hepatitis C.
Seminars in liver disease
1999

Determination of HCV-Specific Bulk CD8(+) Activity in Liver.
Methods in molecular medicine
1999

Pathogenesis of chronic hepatitis C virus infection
Therapies for Viral Hepatitis
1998

Pathogenesis of chronic hepatitis C virus infection.
Antiviral therapy
1998

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.
Hepatology (Baltimore, Md.)
1998

Treatment of chronic hepatitis C.
Comprehensive therapy
1997

Transforming growth factor-beta 1 in chronic hepatitis C.
Journal of viral hepatitis
1997

The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C.
Journal of immunology (Baltimore, Md. : 1950)
1997

Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection.
Clinics in liver disease
1997

Elevated serum interleukin 4 and interleukin 10 in patients with chronic hepatitis C virus infection
J Hepatol
1997

Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.
Digestive diseases and sciences
1997

Host immune response in hepatitis C virus infection
Viral Hepatitis Reviews
1996

Anti-GOR in chronic HCV patients with membranoproliferative glomerulonephritis.
Journal of hepatology
1996

alpha-Glutathione S-transferase as a marker of hepatocellular damage in chronic hepatitis C virus infection.
American journal of clinical pathology
1995

Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy.
Journal of viral hepatitis
1995